Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) EPS (Basic): 2010-2025

Historic EPS (Basic) for Aytu Biopharma (AYTU) over the last 12 years, with Sep 2025 value amounting to $0.20.

  • Aytu Biopharma's EPS (Basic) rose 219.95% to $0.20 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.24, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$2.26 for FY2025, which is 20.98% up from last year.
  • Aytu Biopharma's EPS (Basic) amounted to $0.20 in Q3 2025, which was up 1,872.95% from $0.01 recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's EPS (Basic) ranged from a high of $0.20 in Q3 2025 and a low of -$35.90 during Q1 2022.
  • For the 3-year period, Aytu Biopharma's EPS (Basic) averaged around -$0.44, with its median value being -$0.04 (2023).
  • In the last 5 years, Aytu Biopharma's EPS (Basic) tumbled by 6,117.14% in 2021 and then soared by 219.95% in 2025.
  • Aytu Biopharma's EPS (Basic) (Quarterly) stood at -$8.74 in 2021, then surged by 75.40% to -$2.15 in 2022, then soared by 98.14% to -$0.04 in 2023, then surged by 150.01% to $0.02 in 2024, then skyrocketed by 219.95% to $0.20 in 2025.
  • Its last three reported values are $0.20 in Q3 2025, $0.01 for Q2 2025, and $0.01 during Q1 2025.